Our SMARxT Tissue-Specific TM Platform oncology drug candidates employ our proprietary TME Normalization TM Technology. TME Normalization Technology allows our therapies to circulate in the bloodstream, then exit through porous tumor blood vessels, accumulating in the TME.

The TME is made up of a tightly packed mass of: 1) cancer associated fibroblasts, or CAFs, 2) tumor-associated macrophages/immune cells, or TAMs, and 3) cancer itself. TME Normalization Technology enables precision delivery of our therapies to the TME, simultaneously attacking all 3 components of the TME, severing the critical lifelines between the tumor and the its metabolic and structural support. 

Cancer is an evolvable and adaptable system relying on recurrent waves of self-sustaining inflammation, controlled by multiple system transduction systems. Multi-target inhibition enables  ImmixBio’s Tissue Specific Therapeutics (TSTx) TM to cause tumor apoptosis while blocking multiple tumor escape pathways.

Tumor apoptosis is a non-inflammatory tumor-cell death pathway (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).